dwinnex.com

The Chemours Company [NYSE:CC]: Analyst Rating and Earnings

Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to The Chemours Company [CC], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give CC an Outperform rating. Its stock price has been found in the range of 23.36 to 53.25. This is compared to its latest closing price of $23.93.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for The Chemours Company [CC] is sitting at 2.14. This is compared to 1 month ago, when its average rating was 2.07.

For the quarter ending in Mar-19 The Chemours Company [CC] generated $1.38 billion in sales. That’s 7.94% lower than the average estimate of $1.49 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.

Keep your eyes on this company’s next financial results, which are scheduled to be made public on Thu 1 Aug (In 76 Days).

Fundamental Analysis of The Chemours Company [CC]

Now let’s turn to look at profitability: with a current Operating Margin for The Chemours Company [CC] sitting at +18.50 and its Gross Margin at +30.17, this company’s Net Margin is now 12.60%. These measurements indicate that The Chemours Company [CC] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 24.64, and its Return on Invested Capital has reached 19.60%. Its Return on Equity is 106.19, and its Return on Assets is 13.58. These metrics all suggest that The Chemours Company is doing well at using the money it earns to generate returns.

Turning to investigate this organization’s capital structure, The Chemours Company [CC] has generated a Total Debt to Total Equity ratio of 391.72. Similarly, its Total Debt to Total Capital is 79.66, while its Total Debt to Total Assets stands at 53.95. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 390.43, and its Long-Term Debt to Total Capital is 79.40. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is 4.76 and its Total Debt to EBITDA Value is 2.63. The Enterprise Value to Sales for this firm is now 1.14, and its Total Debt to Enterprise Value stands at 0.50. The Chemours Company [CC] has a Price to Book Ratio of 4.75, a Price to Cash Flow Ratio of 4.52 and P/E Ratio of 5.30. These metrics all suggest that The Chemours Company is more likely to generate a positive ROI.

Shifting the focus to workforce efficiency, The Chemours Company [CC] earns $948,286 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.46 and its Total Asset Turnover is 0.91. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.26 and its Current Ratio is 1.93. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

The Chemours Company [CC] has 165.24M shares outstanding, amounting to a total market cap of $3.95B. Its stock price has been found in the range of 23.36 to 53.25. At its current price, it has moved by -56.29% from its 52-week high, and it has moved -0.36% from its 52-week low.

This stock’s Beta value is currently 2.23, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 12.60. This stock, according to these metrics, is currently Oversold.

Conclusion: Is The Chemours Company [CC] a Reliable Buy?

Shares of The Chemours Company [CC], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.